Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,751 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platinum-based Chemotherapy Clear all
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00003996
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, chemotherapy, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

NCT00025259
View directory record Official record
Conditions
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
1,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
153
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 16, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer

NCT00004897
View directory record Official record
Conditions
Esophageal Cancer
Interventions
recombinant interferon alfa, cisplatin, fluorouracil, hydroxyurea, leucovorin calcium, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Results available

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

NCT00705874
View directory record Official record
Conditions
Cancer
Interventions
CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab, CGC-11047 and erlotinib, CGC-11047 and cisplatin, CGC-11047 and 5-flurouracil / leucovorin, CGC-11047 and sunitinib
Drug
Lead sponsor
Progen Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

NCT00388154
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Gemcitabine, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00024323
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Tucson, Arizona • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

NCT00667342
View directory record Official record
Conditions
Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions
Bevacizumab, Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, etoposide, Surgery, Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
5
States / cities
San Diego, California • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

NCT00009880
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 16, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil

NCT00400205
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oral Cancer
Interventions
Docetaxel, Cisplatin, 5-fluorouracil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 16, 2026, 5:57 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

NCT01450696
View directory record Official record
Conditions
Gastric Cancer
Interventions
Capecitabine, Cisplatin, Herceptin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Whittier, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Results available

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864
View directory record Official record
Conditions
Neoplasms
Interventions
Veliparib + VX-970 + Cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

NCT02567409
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer

NCT00858663
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
intensity modulated radiation therapy, RAD001 (everolimus) + Cisplatin
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 16, 2026, 5:57 AM EDT
Recruiting Phase 3 Interventional

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

NCT03067181
View directory record Official record
Conditions
Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions
Best Practice, Biopsy Procedure, Biospecimen Collection, Bleomycin Sulfate, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Pulmonary Function Test, Questionnaire Administration
Other · Procedure · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 338 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate

NCT00165516
View directory record Official record
Conditions
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions
Cisplatin, Sodium Thiosulfate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 16, 2026, 5:57 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2
Biological · Radiation · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
68
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 16, 2026, 5:57 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

NCT05092958
View directory record Official record
Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
271
States / cities
Phoenix, Arizona • Auburn, California • Berkeley, California + 214 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer

NCT00545948
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
West Palm Beach, Florida • Chicago, Illinois • Charlotte, North Carolina + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 16, 2026, 5:57 AM EDT
Completed No phase listed Observational Results available

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

NCT04552535
View directory record Official record
Conditions
Squamous Non-small Cell Lung Cancer
Interventions
Second line (2L) afatinib, Second line chemotherapy
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

NCT02381535
View directory record Official record
Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

NCT00002913
View directory record Official record
Conditions
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
paclitaxel, cisplatin, topotecan hydrochloride, filgrastim
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

NCT02885974
View directory record Official record
Conditions
Bladder Cancer
Interventions
Celecoxib, Gemcitabine, Cisplatin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Study in Advanced Solid Tumors

NCT01099358
View directory record Official record
Conditions
Solid Tumor
Interventions
Cetuximab, Cisplatin, 5 - Fluorouracil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 16, 2026, 5:57 AM EDT
Withdrawn Phase 1 Interventional

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

NCT02639767
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI
Drug · Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • East White Plains, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 16, 2026, 5:57 AM EDT